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We measured antifungal activity against 128 cryptococcal isolates (86 of C. neoformans and 42 of C. gattii) to
determine if differences in serotype susceptibility exist. Contrary to previous results, we found no serotype
susceptibility differences. Isavuconazole, posaconazole, and voriconazole demonstrated excellent potency
against each isolate and serotype, including isolates with reduced fluconazole susceptibilities.
Cryptococcosis is an invasive fungal infection most com-
monly caused by one of two species of encapsulated yeast,
Cryptococcus neoformans and Cryptococcus gattii. Although
previously classified as three C. neoformans varieties, proposed
taxonomic changes have redefined C. neoformans and C. gattii
as distinct species consisting of five serotypes: C. neoformans
var. grubii (serotype A), C. neoformans var. neoformans (sero-
type D), the hybrid serotype AD, and C. gattii (serotypes B and
C) (9). Immunocompromised patients are most commonly in-
fected with serotypes A or D, while C. gattii has emerged as an
important cause of infection for immunocompetent hosts, as
illustrated by the recent outbreak on Vancouver Island, BC,
Canada (6).
The incidence of cryptococcal meningitis has fallen after the
introduction of antiretroviral therapy, although immunosup-
pressed populations remain at risk. Existing guidelines pub-
lished by the Infectious Diseases Society of America do not
define treatment differences by Cryptococcus spp., and for se-
vere or central nervous system infections, a combination of
amphotericin B and flucytosine remains the standard of care
(14). However, previous reports of infections caused by C. gattii
illustrate significant differences in the epidemiology, suscepti-
bility patterns, chronicity of infection, and higher frequency of
neurosurgical intervention than infections caused by C. neofor-
mans; this is likely due to the propensity of C. gattii to form
cryptococcomas (7, 17). These species’ differences have
prompted the search for antifungal agents with greater activity
against C. gattii. Our objective was to measure the in vitro
activities of antifungals against various cryptococcal serotypes
to determine if differences in susceptibility exist. We also
sought to determine the activity of the new extended-spectrum
triazole, isavuconazole (formerly BAL4815), against C. gattii,
as in vitro evaluation of this agent against a significant number
of serotype B and C isolates has not previously been reported.
(This study was presented at the 48th Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy/46th Annual
Meeting of the Infectious Diseases Society of America, Wash-
ington, DC, 2008.)
A total of 128 Cryptococcus isolates were evaluated, includ-
ing 86 isolates of C. neoformans (28 of serotype A, 25 of
serotype D, and 33 of the hybrid AD serotype) and 42 isolates
of C. gattii (30 of serotype B and 12 of serotype C), and were
collected from both clinical and environmental sources from
the United States, Australia, France, Denmark, Italy, Thai-
land, and the Democratic Republic of the Congo. Isolates were
subcultured at least twice on Sabouraud dextrose agar (Remel,
Inc., Lenexa, KS) prior to in vitro susceptibility testing. The
previously available Crypto Check kit (Iatron Laboratories,
Tokyo, Japan) was discontinued in 2004, so serotype identifi-
cation of all isolates in this study was performed using a pre-
viously validated multiplex PCR method (4) and species were
confirmed by growth/lack of growth on canavanine-glycine-
bromothymol blue medium (8).
Susceptibility testing was done by broth microdilution in
accordance with the CLSI M27-A2 methodology (12). Anti-
fungals were obtained from the manufacturers as follows: isa-
vuconazole (Basilea Pharmaceutica Ltd.), fluconazole (Pfizer),
posaconazole (Schering-Plough), voriconazole (Pfizer), flucy-
tosine (ICN Pharmaceuticals), and amphotericin B deoxy-
cholate (Bristol-Myers Squibb). Stock solutions were prepared
in dimethyl sulfoxide (isavuconazole, voriconazole, and am-
photericin B), polyethylene glycol (posaconazole), or water
(fluconazole and flucytosine) and were further diluted in
RPMI 1640 medium (Sigma, St. Louis, MO) buffered to a pH
of 7.0 with morpholinepropanesulfonic acid. Aliquots of each
agent (0.1 ml) at 2 concentrations were dispensed into 96-
well microdilution trays. Inocula containing 0.5  103 to 2.5 
103 cells/ml were added, and trays were incubated at 35°C.
Final antifungal concentrations ranged from 0.015 to 8 g/ml
for isavuconazole, posaconazole, voriconazole, and amphoter-
icin and from 0.25 to 64 g/ml for fluconazole and flucytosine.
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The MICs for isavuconazole, posaconazole, voriconazole, flu-
conazole, and flucytosine were read as a 50% reduction in
turbidity compared to growth control at 72 h. For amphotericin
B, MICs were determined to have 100% inhibition relative to
that of growth controls. Candida krusei ATCC 6258 and Can-
dida parapsilosis ATCC 22019 were used as quality controls.
Differences in geometric mean (GM) MICs were assessed by
analysis of variance with Tukey’s posttest for multiple compar-
isons.
The antifungal agents tested retained activity against all
cryptococcal isolates. Table 1 summarizes the ranges and the
MIC50 and MIC90 values against the C. neoformans and C.
gattii isolates for each antifungal. The MIC50 and MIC90 values
for isavuconazole (0.015 and 0.06 g/ml for C. neoformans
and 0.03 and 0.06 g/ml for C. gattii, respectively) were lower
or equivalent to the corresponding values of all other antifun-
gals. These results are consistent with those previously re-
ported for Candida spp., with isavuconazole demonstrating
lower MIC50 and MIC90 values than other agents (16). Similar
potency was also observed for posaconazole and voriconazole.
Excellent activity against isolates with intermediate suscepti-
bility to fluconazole (MIC, 16 to 64 g/ml) was also maintained
for isavuconazole (0.06 to 0.5 g/ml), posaconazole (0.125 to
0.5 g/ml), and voriconazole (0.25 to 0.5 g/ml).
When separated by serotype (Table 2), similar results were
also observed. Isavuconazole, posaconazole, and voriconazole
were active against each serotype (MIC90  0.25 g/ml) and
were more potent than the other agents tested when compared
using geometric mean (GM) MICs (P  0.05). Fluconazole
and flucytosine were the least potent (MIC90, 4 or 8 g/ml
against each serotype). Reduced flucytosine susceptibility in
our study (23% MIC  4 g/ml) was higher than that previ-
ously reported (11%) (13). The clinical implications of this are
unknown, as flucytosine is used in combination with ampho-
tericin B and in vitro data have demonstrated synergy even
against resistant isolates (MIC  32 g/ml) (15).
Few differences were observed among the serotypes for each
agent. Interestingly, no significant differences in potency were
found for serotype B or C (C. gattii) compared to those of the
other serotypes. This is consistent with the largest published
TABLE 1. MIC range, GM, and MIC50 and MIC90 values for antifungal
agents against all C. neoformans (n  86) and C. gattii (n  42)
isolates tested
Isolate and antifungal
agent MIC range GM MIC50 MIC90
Cryptococcus neoformans
Amphotericin B 0.03–1 0.186 0.25 0.5
Flucytosine 0.25–16 3.6 4 8
Fluconazole 0.25–64 1.95 2 4
Posaconazole 0.015–0.5 0.034 0.03 0.06
Voriconazole 0.015–0.5 0.069 0.06 0.25
Isavuconazole 0.015–0.5 0.023 0.015 0.06
Cryptococcus gattii
Amphotericin B 0.125–1 0.24 0.25 0.25
Flucytosine 0.06–16 1.97 2 8
Fluconazole 0.5–32 2.36 2 8
Posaconazole 0.015–0.25 0.041 0.03 0.125
Voriconazole 0.015–0.5 0.098 0.125 0.25
Isavuconazole 0.015–0.25 0.026 0.03 0.06
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series evaluating species-specific MICs that reported no differ-
ences among serotypes (2, 11, 19). Other studies have de-
scribed serotype-specific differences in antifungal potency (1, 3,
5, 10, 18, 21), raising concerns that infection with C. gattii may
be met with a slower response to therapy (11), yet no consistent
or predictable differences in antifungal activity were reported.
In this study, posaconazole, voriconazole, and the new tria-
zole, isavuconazole, demonstrated excellent in vitro activity
against all Cryptococcus serotypes tested, including isolates
with reduced fluconazole susceptibility. This suggests extended-
spectrum triazoles may be alternative treatments when similar
isolates are encountered in clinical practice. However, clinical
data are needed to confirm these results.
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